Soleno Therapeutics (NASDAQ:SLNO) Rating Lowered to Hold at Piper Sandler

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by Piper Sandler from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research analysts have also issued reports on SLNO. Wells Fargo & Company dropped their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Lifesci Capital downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. TD Cowen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $53.00 in a report on Tuesday. Finally, Wall Street Zen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $89.20.

Soleno Therapeutics Trading Up 0.5%

Shares of Soleno Therapeutics stock opened at $52.60 on Tuesday. Soleno Therapeutics has a 52-week low of $29.43 and a 52-week high of $90.32. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The company’s 50-day simple moving average is $38.39 and its 200-day simple moving average is $47.83. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of 228.71 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. As a group, equities research analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of institutional investors have recently modified their holdings of SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after buying an additional 189 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Soleno Therapeutics by 50.9% in the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock valued at $45,236,000 after buying an additional 213,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Soleno Therapeutics by 48.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock valued at $2,909,000 after buying an additional 13,211 shares during the last quarter. Creative Planning acquired a new position in shares of Soleno Therapeutics in the second quarter valued at approximately $338,000. Finally, Prudential Financial Inc. acquired a new position in shares of Soleno Therapeutics in the second quarter valued at approximately $413,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine acquisition drives rally — Neurocrine agreed to acquire Soleno in a cash deal near $53/share (reported deal value ~$2.9B), adding VYKAT (DCCR) to its portfolio; that takeover/offer price is the main catalyst lifting SLNO shares this week. Zacks: Soleno Therapeutics Stock Rallies
• Neutral Sentiment: EU marketing application withdrawn ahead of takeover — Soleno voluntarily withdrew its European marketing application for the rare‑disease drug as Neurocrine sharpens focus on the U.S. market; this reduces near‑term EU optionality but appears tactical given the pending acquisition. Reuters: Soleno withdraws EU application
• Neutral Sentiment: Mixed analyst stance — HC Wainwright reiterated a “neutral” rating and cut its price target to $53 (from $100), signaling analysts are aligning targets close to the deal price; that limits upside absent a competing bidder or a higher offer. Benzinga coverage
• Negative Sentiment: Class‑action over alleged misstatements — Multiple plaintiff firms have filed/announced investigations and are soliciting lead plaintiffs for a securities‑fraud suit covering March 26–Nov 4, 2025 (alleging misstatements about the DCCR Phase 3 program); May 5, 2026 is the lead‑plaintiff deadline. This creates legal and reputational overhang that can pressure the stock and complicate the deal transition. PR Newswire: Deadline in securities fraud class action
• Negative Sentiment: Multiple downgrades trim expectations — A string of firms (Wolfe, TD Cowen, Piper Sandler, Baird, Cantor Fitzgerald, Lifesci, etc.) cut ratings/targets to “hold” or similar and trimmed price targets toward ~$53, reflecting deal‑price anchoring and reduced standalone upside; analyst caution can weigh on buyers absent a higher bid or new data. Zacks: analyst downgrade coverage

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.